HomeCompareSRRA vs SBUX

SRRA vs SBUX: Dividend Comparison 2026

SRRA yields 3.64% · SBUX yields 2.84%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SBUX wins by $141.7K in total portfolio value
10 years
SRRA
SRRA
● Live price
3.64%
Share price
$54.99
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.3K
Annual income
$459.50
Full SRRA calculator →
SBUX
SBUX
● Live price
2.84%
Share price
$86.72
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$167.0K
Annual income
$71,136.45
Full SBUX calculator →

Portfolio growth — SRRA vs SBUX

📍 SBUX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSRRASBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SRRA + SBUX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SRRA pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SRRA
Annual income on $10K today (after 15% tax)
$309.15/yr
After 10yr DRIP, annual income (after tax)
$390.58/yr
SBUX
Annual income on $10K today (after 15% tax)
$241.12/yr
After 10yr DRIP, annual income (after tax)
$60,465.98/yr
At 15% tax rate, SBUX beats the other by $60,075.41/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SRRA + SBUX for your $10,000?

SRRA: 50%SBUX: 50%
100% SBUX50/50100% SRRA
Portfolio after 10yr
$96.2K
Annual income
$35,797.98/yr
Blended yield
37.23%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

SRRA
Analyst Ratings
3
Buy
3
Hold
Consensus: Buy
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+19.9% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SRRA buys
0
SBUX buys
0
No recent congressional trades found for SRRA or SBUX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSRRASBUX
Forward yield3.64%2.84%
Annual dividend / share$2.00$2.46
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%48.3%
Portfolio after 10y$25.3K$167.0K
Annual income after 10y$459.50$71,136.45
Total dividends collected$4.1K$136.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusBuyBuy

Year-by-year: SRRA vs SBUX ($10,000, DRIP)

YearSRRA PortfolioSRRA Income/yrSBUX PortfolioSBUX Income/yrGap
1← crossover$11,064$363.70$11,121$420.68$57.00SBUX
2$12,214$376.07$12,548$648.40$334.00SBUX
3$13,457$388.01$14,440$1,013.98$983.00SBUX
4$14,799$399.53$17,068$1,617.30$2.3KSBUX
5$16,245$410.62$20,912$2,649.52$4.7KSBUX
6$17,804$421.26$26,875$4,499.29$9.1KSBUX
7$19,481$431.47$36,771$8,014.12$17.3KSBUX
8$21,286$441.25$54,542$15,197.11$33.3KSBUX
9$23,227$450.59$89,602$31,242.49$66.4KSBUX
10$25,312$459.50$167,011$71,136.45$141.7KSBUX

SRRA vs SBUX: Complete Analysis 2026

SRRAStock

Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It has the license agreements with Carna Biosciences, Inc. to develop and commercialize SRA141, a small molecule kinase inhibitor targeting Cdc7; AstraZeneca AB; and CRT Pioneer Fund LP. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is headquartered in San Mateo, California. As of July 1, 2022, Sierra Oncology, Inc. operates as a subsidiary of GSK plc.

Full SRRA Calculator →

SBUXConsumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this SRRA vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SRRA vs SCHDSRRA vs JEPISRRA vs OSRRA vs KOSRRA vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.